Business Description
![Panbela Therapeutics Inc Panbela Therapeutics Inc logo](https://static.gurufocus.com/logos/0C0000APEW.png?14)
Panbela Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US69833W4042
Share Class Description:
STU:X70: Ordinary SharesDescription
Panbela Therapeutics Inc is a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The Company's pipeline assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X), which provide a multi-targeted approach to reset dysregulated biology present in many types of diseases such as cancer and autoimmunity.
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.06 | |||||
Equity-to-Asset | -0.3 | |||||
Debt-to-Equity | -1.32 | |||||
Debt-to-EBITDA | -0.15 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 76.6 | |||||
3-Year EPS without NRI Growth Rate | 25 | |||||
3-Year FCF Growth Rate | 74.4 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History |
---|
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.17 | |||||
Quick Ratio | 0.17 | |||||
Cash Ratio | 0.02 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -962.7 | |||||
Shareholder Yield % | -735.5 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROA % | -197.57 | |||||
ROIC % | -276.54 | |||||
ROCE % | -806.5 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
EV-to-EBIT | -0.21 | |||||
EV-to-Forward-EBIT | -0.08 | |||||
EV-to-EBITDA | -0.21 | |||||
EV-to-Forward-EBITDA | -0.08 | |||||
EV-to-FCF | -0.24 | |||||
Earnings Yield (Greenblatt) % | -471.3 | |||||
FCF Yield % | -1428.1 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Panbela Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -211.633 | ||
Beta | 0 | ||
Volatility % | 0 | ||
14-Day RSI | 0 | ||
14-Day ATR (€) | 0 | ||
20-Day SMA (€) | 119.4 | ||
12-1 Month Momentum % | 0 | ||
52-Week Range (€) | 119.4 - 119.4 | ||
Shares Outstanding (Mil) | 4.85 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Panbela Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Panbela Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Panbela Therapeutics Inc Frequently Asked Questions
What is Panbela Therapeutics Inc(STU:X70)'s stock price today?
The current price of STU:X70 is €119.40. The 52 week high of STU:X70 is €119.40 and 52 week low is €119.40.
When is next earnings date of Panbela Therapeutics Inc(STU:X70)?
The next earnings date of Panbela Therapeutics Inc(STU:X70) is 2024-08-09 Est..
Does Panbela Therapeutics Inc(STU:X70) pay dividends? If so, how much?
Panbela Therapeutics Inc(STU:X70) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |